kitov pharmaceuticals ltd. is a financial services company located in israel.
Company profile
Ticker
PPBT
Exchange
Website
CEO
Itzhak Israel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Kitov Pharma Ltd., Kitov Pharmaceuticals Holdings Ltd.
SEC CIK
PPBT stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
3 Apr 24
POS AM
Prospectus update (post-effective amendment)
28 Mar 24
6-K
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
28 Mar 24
6-K
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
14 Mar 24
6-K
Report of Foreign Private Issuer
6 Mar 24
20-F
2023 FY
Annual report (foreign)
5 Mar 24
6-K
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24
6-K
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
27 Feb 24
6-K
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
13 Feb 24
6-K
Report of Foreign Private Issuer
1 Feb 24
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
MORGAN STANLEY
9 Apr 21
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
Nussbaum Ran
5 Feb 21
SC 13G
MORGAN STANLEY
4 Feb 21
SC 13G/A
SABBY MANAGEMENT, LLC
5 Jan 21
SC 13G
ARMISTICE CAPITAL, LLC
6 Jul 20
SC 13G
ARMISTICE CAPITAL, LLC
15 May 20
SC 13G
SABBY MANAGEMENT, LLC
6 May 20
SC 13G
ARMISTICE CAPITAL, LLC
23 Mar 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
6.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 373.99 mm |
Total shares | 1.62 mm |
Total puts | 3.50 k |
Total calls | 39.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.35 mm | $5.14 mm |
Kingswood Wealth Advisors | 127.95 k | $178.49 mm |
Citadel Advisors | 45.94 k | $64.32 mm |
MS Morgan Stanley | 29.63 k | $41.34 mm |
Venture Visionary Partners | 13.72 k | $19.14 mm |
Wealth Advisors of Iowa | 13.27 k | $18.51 mm |
Geode Capital Management | 12.67 k | $17.73 mm |
Raymond James & Associates | 11.00 k | $15.35 mm |
Simplex Trading | 9.16 k | $12.00 k |
Fiduciary Alliance | 5.41 k | $7.55 mm |
News
Chardan Capital Maintains Buy on Purple Biotech, Maintains $11 Price Target
7 Mar 24
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
5 Mar 24
Purple Biotech Q4 EPS $(0.19), Inline
5 Mar 24
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
27 Feb 24
Purple Biotech Says Determined 100Mg/Kg Is The Recommended Phase 2 Dose For NT219 In Combination With Cetuximab In The Treatment Of Head And Neck Cancer Based On Its Phase 1/2 Dose Escalation Study
1 Feb 24
Press releases
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
14 Mar 24
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
27 Feb 24
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
13 Feb 24
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
1 Feb 24